|
PRDM4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.47090000027717E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.03339999998997E-05 |
| Normal-vs-Stage2 |
5.020400E-04 |
| Normal-vs-Stage3 |
2.51880000001758E-06 |
| Normal-vs-Stage4 |
1.81590000003506E-06 |
| Stage1-vs-Stage2 |
6.651200E-01 |
| Stage1-vs-Stage3 |
2.536400E-01 |
| Stage1-vs-Stage4 |
2.146400E-01 |
| Stage2-vs-Stage3 |
7.368200E-01 |
| Stage2-vs-Stage4 |
6.662200E-01 |
| Stage3-vs-Stage4 |
8.796000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.46270000003879E-06 |
| Normal-vs-AfricanAmerican |
3.531900E-02 |
| Normal-vs-Asian |
6.995900E-03 |
| Caucasian-vs-AfricanAmerican |
4.584800E-01 |
| Caucasian-vs-Asian |
3.685800E-01 |
| AfricanAmerican-vs-Asian |
9.418000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.63440999999542E-05 |
| Normal-vs-Female |
1.25949999996156E-06 |
| Male-vs-Female |
8.864400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.20409999999572E-05 |
| Normal-vs-Age(41-60Yrs) |
2.22509999999732E-05 |
| Normal-vs-Age(61-80Yrs) |
8.31970000003679E-07 |
| Normal-vs-Age(81-100Yrs) |
8.154700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.551000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.286800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.352600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.533800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.233170E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.949600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.935600E-02 |
| Classical-VS-Follicular |
2.984800E-03 |
| Classical-VS-Other |
6.533400E-01 |
| Classical-VS-Normal |
7.441800E-04 |
| Tall-VS-Follicular |
7.742200E-01 |
| Tall-VS-Other |
8.989000E-01 |
| Tall-VS-Normal |
1.87740999999519E-05 |
| Follicular-VS-Other |
7.757200E-01 |
| Follicular-VS-Normal |
7.6256000003383E-07 |
| Other-VS-Normal |
2.628400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.5598999998695E-07 |
| Normal-vs-N1 |
1.40250000002506E-06 |
| N0-vs-N1 |
4.403000E-01 |
|
|
